GeneDx Holdings Q3 2026 Results: Net Loss of $12.3M, Loss Widens
For the nine months ended September 30, 2026, GeneDx reported total revenue of $339.8 million, an 11% increase year-over-year, though net loss widened significantly to $93.4 million due to a $31.3 million impairment loss and increased SG&A expenses. The company strengthened its balance sheet by securing $146.0 million in long-term debt proceeds while repaying its previous Perceptive debt facility.
- Key figure
- Net loss $12.3M